Experienced in Lung Metastases

Geon K. Lee

Anticancer Resistance Branch, 
Goyang, KR 
Experienced in Lung Metastases
Anticancer Resistance Branch, 
Goyang, KR 
OverviewLocationsClinical Research

Overview

Geon Lee practices in Goyang, Republic of Korea. Mr. Lee is rated as an Experienced expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Lung Adenocarcinoma, EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lung Metastases.

Gender
Male

Locations

Anticancer Resistance Branch, Goyang, Republic of Korea
Other Locations
Anticancer Resistance Branch, Goyang, Gyeonggi-do, Republic of Korea
Ansan, Republic of Korea
Goyang-si, Republic of Korea
Cheongju-si, 362763, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase II Study of Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
A Randomized Phase II Study of Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
Enrollment Status: Unknown
Publish Date: April 06, 2022
Intervention Type: Drug
Study Drugs: IP chemotherapy, IP chemotherapy+Simvastatin
Study Phase: Phase 2

73 Total Publications

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
Journal: MedComm
Published: December 30, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lee's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile